Scientists Reprogram Brain Immune Cells to Combat Alzheimer’s Disease, Study Finds

Yesterday 18:35

Scientists have identified a promising experimental approach that may help the brain fight Alzheimer’s disease by reprogramming its own immune cells, according to a new study published in Cell Death and Disease.

The research, conducted by teams in Spain and Switzerland, focused on a molecule called OLE, which appears to restore the protective function of microglia — the brain’s immune cells that normally help clear toxic waste but become less effective in Alzheimer’s patients.

In laboratory and animal experiments, OLE was shown to reduce the accumulation of beta-amyloid plaques, one of the key hallmarks of Alzheimer’s disease. These toxic protein deposits are known to damage neurons and contribute to memory loss and cognitive decline.

Researchers found that after treatment with OLE, microglia regained their ability to move toward these plaques, surround them, and limit their harmful impact on brain tissue. This process significantly reduced plaque size and improved brain function in experimental models.

The study involved multiple stages of testing, including genetically modified worms and mouse models of Alzheimer’s disease. In both cases, treated subjects showed improved cognitive performance and reduced levels of toxic protein buildup compared to untreated groups.

Scientists also conducted single-cell analyses, revealing that microglia were the primary brain cells responding to the treatment. The findings suggest that OLE activates biological pathways linked to plaque clearance and cellular repair.

In addition to improving immune response, the molecule was also observed to enhance neuron survival in laboratory conditions, indicating potential dual benefits for brain protection.

Researchers describe the discovery as a significant step toward developing new therapeutic strategies for Alzheimer’s disease, a condition that currently affects tens of millions of people worldwide and has no definitive cure.

Although the results are still in early experimental stages, the study has already been protected by European patents, highlighting its potential for future clinical development.